Horizon 2020: Clinical research on regenerative medicine

Specific research is needed for proving safety, efficacy and repeatability of new treatments in regenerative medicine. The, very often iterative, dialogue between the relevant authorities and those developing regenerative medicine approaches is needed before specific regulatory requirements can be established.

Horizon 2020 welcomes applications to finance clinical-stage research in regenerative medicine. Proposals should have at the time of proposal submission the necessary ethical and regulatory authorisations to carry out the work or provide evidence of regulatory engagement and that such approval is close. Preference will be given to proposals which have or are closest to having approvals in place for clinical work to start.

The deadline for applications is 15 April 2015. More information is available on the European Commission's Horizon 2020 website.